{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:38:30Z","timestamp":1760027910172},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"15","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,8,1]]},"DOI":"10.1093\/eurheartj\/ehi181","type":"journal-article","created":{"date-parts":[[2005,3,31]],"date-time":"2005-03-31T01:14:11Z","timestamp":1112231651000},"page":"1506-1512","source":"Crossref","is-referenced-by-count":10,"title":["Prognostic implication of activated partial thromboplastin time after reteplase or half-dose reteplase plus abciximab: results from the GUSTO-V trial"],"prefix":"10.1093","volume":"26","author":[{"given":"Brahmajee K.","family":"Nallamothu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric R.","family":"Bates","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith S.","family":"Hochman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher B.","family":"Granger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor","family":"Guetta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert G.","family":"Wilcox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harvey D.","family":"White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul W.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Savonitto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gang","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. Michael","family":"Lincoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric J.","family":"Topol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2005,3,30]]},"reference":[{"key":"key\n\t\t\t\t20171012061129_EHI181C1","doi-asserted-by":"crossref","unstructured":"Hirsh J, Anand SS, Halperin JL et\u00a0al. Guide to anticoagulant therapy: heparin: a statement for healthcare professionals from the American Heart Association. Circulation2001;103:2994\u20133018.","DOI":"10.1161\/01.CIR.103.24.2994"},{"key":"key\n\t\t\t\t20171012061129_EHI181C2","doi-asserted-by":"crossref","unstructured":"Granger CB, Hirsh J, Califf RM et\u00a0al. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I trial. Circulation1996;93:870\u2013878.","DOI":"10.1161\/01.CIR.93.5.870"},{"key":"key\n\t\t\t\t20171012061129_EHI181C3","doi-asserted-by":"crossref","unstructured":"Antman EM, Anbe DT, Armstrong PW et\u00a0al. ACC\/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology\/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol2004;44:E1\u2013E211.","DOI":"10.1016\/j.jacc.2004.07.014"},{"key":"key\n\t\t\t\t20171012061129_EHI181C4","doi-asserted-by":"crossref","unstructured":"The GUSTO V Investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb\/IIIa inhibition: the GUSTO V randomised trial. Lancet2001;357:1905\u20131914.","DOI":"10.1016\/S0140-6736(00)05059-5"},{"key":"key\n\t\t\t\t20171012061129_EHI181C5","doi-asserted-by":"crossref","unstructured":"The ASSENT-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet2001;358:605\u2013613.","DOI":"10.1016\/S0140-6736(01)05775-0"},{"key":"key\n\t\t\t\t20171012061129_EHI181C6","doi-asserted-by":"crossref","unstructured":"Moliterno DJ, Califf RM, Aguirre FV et\u00a0al. Effect of platelet glycoprotein IIb\/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Evaluation of c7E3 Fab in the Prevention of Ischemic Complications trial. Am J Cardiol1995;75:559\u2013562.","DOI":"10.1016\/S0002-9149(99)80616-X"},{"key":"key\n\t\t\t\t20171012061129_EHI181C7","doi-asserted-by":"crossref","unstructured":"Dalby M, Montalescot G, Bal dit Sollier C et\u00a0al. Eptifibatide provides additional platelet inhibition in non-ST-elevation myocardial infarction patients already treated with aspirin and clopidogrel: results of the platelet activity extinction in non-Q-wave myocardial infarction with aspirin, clopidogrel, and eptifibatide (PEACE) study. J Am Coll Cardiol2004;43:162\u2013168.","DOI":"10.1016\/j.jacc.2003.08.033"},{"key":"key\n\t\t\t\t20171012061129_EHI181C8","doi-asserted-by":"crossref","unstructured":"Merlini PA, Repetto A, Andreoli AM et\u00a0al. Effect of abciximab on prothrombin activation and thrombin generation in patients with acute myocardial infarction also receiving reteplase. Am J Cardiol2004;93:195\u2013198.","DOI":"10.1016\/j.amjcard.2003.09.036"},{"key":"key\n\t\t\t\t20171012061129_EHI181C9","doi-asserted-by":"crossref","unstructured":"The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb\/IIIa receptor in high-risk coronary angioplasty. N Engl J Med1994;330:956\u2013961.","DOI":"10.1056\/NEJM199404073301402"},{"key":"key\n\t\t\t\t20171012061129_EHI181C10","doi-asserted-by":"crossref","unstructured":"The EPILOG Investigators. Platelet glycoprotein IIb\/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med1997;336:1689\u20131696.","DOI":"10.1056\/NEJM199706123362401"},{"key":"key\n\t\t\t\t20171012061129_EHI181C11","unstructured":"Narins CR. Heparin: how much in patients undergoing percutaneous coronary intervention? In: Ellis SG, Holmes DR, eds. Strategic Approaches in Coronary Intervention. Philadelphia PA: Lippincott Williams & Wilkins; 2000. p537\u2013549."},{"key":"key\n\t\t\t\t20171012061129_EHI181C12","doi-asserted-by":"crossref","unstructured":"Lee MS, Wali AU, Menon V et\u00a0al. The determinants of activated partial thromboplastin time, relation of activated partial thromboplastin time to clinical outcomes, and optimal dosing regimens for heparin treated patients with acute coronary syndromes: a review of GUSTO-IIb. J Thromb Thrombolysis2002;14:91\u2013101.","DOI":"10.1023\/A:1023235926825"},{"key":"key\n\t\t\t\t20171012061129_EHI181C13","doi-asserted-by":"crossref","unstructured":"Anand SS, Yusuf S, Pogue J et\u00a0al. Relationship of activated partial thromboplastin time to coronary events and bleeding in patients with acute coronary syndromes who receive heparin. Circulation2003;107:2884\u20132888.","DOI":"10.1161\/01.CIR.0000077530.53367.E9"},{"key":"key\n\t\t\t\t20171012061129_EHI181C14","doi-asserted-by":"crossref","unstructured":"Lauer MA, Houghtaling PL, Peterson JG et\u00a0al. Attenuation of rebound ischemia after discontinuation of heparin therapy by glycoprotein IIb\/IIIa inhibition with eptifibatide in patients with acute coronary syndromes: observations from the platelet IIb\/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial. Circulation2001;104:2772\u20132777.","DOI":"10.1161\/hc4801.100358"},{"key":"key\n\t\t\t\t20171012061129_EHI181C15","doi-asserted-by":"crossref","unstructured":"Ross AM, Molhoek P, Lundegan C et\u00a0al. Randomized comparison of enoxaparin, a low-molecular weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: second trial heparin and aspirin reperfusion therapy (HART II). Circulation2001;106:648\u2013652.","DOI":"10.1161\/hc3101.093866"},{"key":"key\n\t\t\t\t20171012061129_EHI181C16","doi-asserted-by":"crossref","unstructured":"Montalescot G, Collet JP, Tanguy ML et\u00a0al. Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin. Circulation2004;110:392\u2013398.","DOI":"10.1161\/01.CIR.0000136830.65073.C7"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/eurheartj\/article-pdf\/26\/15\/1506\/17047674\/ehi181.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,8]],"date-time":"2019-02-08T02:47:09Z","timestamp":1549594029000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/eurheartj\/article\/26\/15\/1506\/541624\/Prognostic-implication-of-activated-partial"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3,30]]},"references-count":16,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2005,3,30]]},"published-print":{"date-parts":[[2005,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehi181","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2005,8]]},"published":{"date-parts":[[2005,3,30]]}}}